Brief: RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Ribomic

05/12/2023 12:34

Dec 5 (Reuters) - Ribomic Inc  4591.T :
    * RIBOMIC PHASE I AND II DATA PUBLISHED IN THE EYE: FULL
TOFU/RAMEN/TEMPURA TRIAL RESULTS DEMONSTRATE CLINICAL PROOF OF
CONCEPT OF UMEDAPTANIB PEGOL IN EXUDATIVE AGE-RELATED MACULAR
DEGENERATION (NAMD)
    * RIBOMIC INC - UMEDAPTANIB PEGOL IS EFFECTIVE IN BLOCKING
SCAR
PROGRESSION
    * RIBOMIC INC: INTRAVITREAL UMEDAPTANIB PEGOL IS SAFE, WELL
TOLERATED, AND EFFECTIVE IN TREATMENT NAÏVE NAMD PATIENTS

Source text for Eikon:  ID:nBw69K1NTa 
Further company coverage:  4591.T 

 ((Reuters.Briefs@thomsonreuters.com;))